Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
KDL Inc.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent given
Able to comply with the study procedures and medication
On a stable HD regimen (at least 3 x per week) for ≥ 3 months
Subject receiving calcium carbonate or sevelamer hydrochloride as a phosphate binder at screening, must have been on a stable regimen (dose and medication) for at least 1 month
A mean serum inorganic phosphorous in the previous 3 tests : \> 5.5 mg/dL and \< 9.0 mg/dL
Removal rate of blood urea nitrogen (BUN) ≥ 60%
Rate of salivary flow by Saxon test ≥ 1 g/2 min
You may not be if
Blood purification therapy other than HD
Current clinically significant intestinal motility disorder
Possible parathyroid intervention during the study period
History of malignancy and severe cardiovascular disorders such as heart disease, angina, congested heart failure, valve stenosis, atrial fibrillation and arrhythmia
History of allergy against active ingredient
Receipt of any investigational drug within 30 days of informed consent
Clareo Health | A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
